摘要
目的探讨microRNA-223（miR-223）表达与弥漫性大B细胞淋巴瘤（DLBCL）免疫亚型及预后的相关关系。方法应用免疫组织化学EnVision法对山西省肿瘤医院病理科有详细随访资料的45例DLBCL进行CD20、CD3、CDl0、bel-6、MUM-1免疫标记，根据Hans分类方法将DLBCL分为生发中心B细胞型（GCB型）和非GCB型；应用安捷伦16．0高密度芯片对24例有详细随访资料的DLBCL患者的石蜡样本进行miRNA表达谱筛选；采用TaqManreal—time逆转录聚合酶链反应（real—timeRT—PCR）检测miR-223的表达水平，14例淋巴结反应性增生样本作为对照。结果45例DLBCL中，GCB型16例（35．6％），非GCB型29例（64．4％）。miR-223在GCB型中的相对表达量为19．8，在非GCB型中的相对表达量为15．8，二者差异无统计学意义（P=0．236）。与淋巴结反应性增生相比较，miR-223在DLBCL中表达上调，其表达量是淋巴结反性增生的17．2倍，差异有统计学意义（P=0．014）。DLBCL中miR-223高表达组（〉中位数）总体生存率高于低表达组（〈中位数），差异有统计学意义（P=0．011）。多因素Cox模型分析显示：45例DLBCL中，miR-223低表达组（RR=5．445，95％CI1．555～19．068，P=0．008）、乳酸脱氢酶异常水平（RR=3．974，95％CI1．191～13．266，P=0．025）、国际预后指数≥3分（RR=4．044，95％CI1．233～13．264，P=0．021）均为各自独立的预后不良的因素。结论DLBCL中miR-223的表达与免疫亚型无关，miR-223高表达组总体生存率明显高于低表达组．提示miR-223可能为评估预后的另一个新型分子标志物。
Objective To study the expression of miR-223 in diffuse large B cell lymphoma （DLBCL） with correlation of histoloigcal subtypes and clinical prognosis. Methods A total of 45- cases of DLBCL were investigated by immunohistochemistry （ EnVision method） for CD20, CD3, CD10, bcl-6 and MUM-1. The cases were classified into germinal center B cell-like （GCB） and non-germinal center B cell- like （non-GCB） subtypes according to Hans＇algorithm. Agilent Human miRNA Microarray 16. 0 was used to detect the expression of micro-RNAs in paraffin-embedded tissue of 24 cases of DLBCL that had available clinical follow-up. The expression levels of miR-223 were examined by TaqMan real-time reverse transcription polymerase chain reaction （real-time RT-PCR）. Fourteen cases of reactive lymph node were selected as control. Results Among 45 cases of DLBCL, 16 cases （35.6%） were GCB／and 29 cases （64. 4% ） were non-GCB subtypes. The expression levels of miR-223 measured by real-time RT-PCR were 19. 8 and 15.8 in GCB and non-GCB subgroups, respectively （P =0. 236）. The expression of miR-223 was up-regulated in DLBCL with 17.2 folds of increase over that of the reactive lymph nodes （P =0. 014）. The overexpression of miR-223 was significantly correlated with a longer overall survival （P = 0. 011 ）. Multivariate Cox proportional hazard regression analysis identified the following independent poor prognostic factors ： low expression of miR-223 （RR = 5. 445, 95% CI, 1. 555-19. 068, P = 0. 008） , abnormal level of LDH （RR=3.974, 95%CI, 1.191-13.266, P=0.025） and IPI≥3 （RR =4.044, 95%CI, 1.233- 13.264, P = 0.021 ）. Conclusions The expression of miR-223 has no relationship with the immunophenotypes of DLBCL. As a potential prognostic biomarker, overexpression of miR-223 correlates with a longer OS of patients with DLBCL.
出处
《中华病理学杂志》
CAS
CSCD
北大核心
2012年第6期366-370,共5页
Chinese Journal of Pathology
基金
山西省国际合作资助项目（2011081059）
山西省留学人员重点科研资助项目（2008-10-5）
关键词
淋巴瘤
大细胞
弥漫型
免疫表型分型
预后
Lymphoma, large B-cell, diffuse
Immunophenotyping
Prognosis
